RxDoctor Payments Data

Sara Domby

Family · Norton, VANPI 1841914348

Payments from drug & device makers

$1,023in general payments, 2019–2025

Across 64 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$233
  • Novo Nordisk$195
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$181
  • Novartis$162
  • Amgen$74
  • Bayer$49
  • plus $129 from 6 others

What the payments were for

  • Food & beverage$1,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,023 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$14,582
Medicare patients
29
Services billed
200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$101,349
EliquisApixaban102$78,339
JardianceEmpagliflozin33$40,489
RybelsusSemaglutide29$27,596
Repatha SureclickEvolocumab24$25,214
FarxigaDapagliflozin Propanediol25$24,745
JanuviaSitagliptin Phosphate27$21,594
Tresiba Flextouch U-100Insulin Degludec24$19,209
TrulicityDulaglutide15$15,059
XareltoRivaroxaban15$10,755
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,500
Emgality PenGalcanezumab-Gnlm11$9,400
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$6,957
Breo ElliptaFluticasone/Vilanterol12$4,805
Dexlansoprazole DrDexlansoprazole18$4,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$195$128,944122 claims
Boehringer IngelheimJardiance$14$40,48933 claims
MerckJanuvia, Janumet Xr$15$25,08539 claims
AstraZenecaFarxiga$32$24,74525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Norton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →